A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

Boston Scientific

Status

Active, not recruiting

Conditions

Mitral Valve Disease

Cardiovascular Diseases

Mitral Regurgitation Functional

Treatments

Device: Millipede Transcatheter Annuloplasty Ring System (Millipede System)

Study type

Interventional

Funder types

Industry

Identifiers

NCT04147884

S2436

Details and patient eligibility

About

To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation

Full description

The Millipede Feasibility Study is a prospective, open-label, single-arm study to assess the safety and feasibility/performance of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation. The study will include subjects with functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are symptomatic (NYHA Class II-IV) despite guideline directed medical therapy in whom the local hearth team determines that surgery is not an option for mitral valve repair. Clinical follow-up will be required in hospital, 30 days, 90 days, 6 months, 12 months, and then annually through 5 years post-procedure. Subjects who have any part of the Millipede Transcatheter Annuloplasty Ring System introduced into the body but who do not end up with an implant will be followed through 30 days.

Enrollment

4 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is 18 years of age or older
Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
Subject has moderate to severe (3+) or severe (4+) functional mitral regurgitation confirmed by echocardiography core lab
Subject is symptomatic (NYHA Class II-IV) despite guideline directed medical therapy, including CRT if indicated
The local site heart team concurs that mitral valve surgery will not be offered as a first-line treatment option
Subject is a candidate for annuloplasty based on the criteria below as assessed by the investigative site (and confirmed by the Case Review Committee [CRC]):

Left Ventricular Ejection Fraction (LVEF) ≥ 25% Left Ventricular End Diastolic Diameter (LVEDD) ≤ 65 mm Coaptation distance (i.e. tenting height) < 10 mm Absence of posterior wall aneurysm

Exclusion criteria

Subject has severe calcification of the mitral annulus or leaflets or other anatomic features that make the subject unsuitable for annuloplasty with the Millipede System in the judgment of the treating physician or subject does not have suitable mitral annular diameter (determined by CT) as per the Instructions for Use
Transfemoral venous and transseptal access determined not to be feasible
Subject is on the waiting list for a transplant or has had a prior heart transplant
Subject has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 30 days prior to study enrollment
Subject has had any percutaneous coronary, carotid, or other endovascular intervention within 30 days prior to study enrollment
Subject has had carotid surgery within 30 days prior to study enrollment
Subject has had any open coronary or vascular surgery (other than carotid surgery) within 3 months prior to study enrollment
Subject has had a cardiac resynchronization therapy (CRT) device implantation within 3 months prior to study enrollment
Subject has untreated clinically significant coronary artery disease requiring revascularization
Any planned cardiac surgery within the next 12 months
Need for emergent or urgent surgery for any reason
Subject has severe aortic valve stenosis and/or aortic valve regurgitation
Subject has physical evidence of right-sided congestive heart failure (CHF) with echocardiographic evidence of moderate or severe right ventricular dysfunction and/or severe tricuspid valve regurgitation
Subject has the presence of prosthetic heart valve in any position
Subject has renal insufficiency (eGFR <20mL/min) and is not on dialysis
Subject has a life expectancy less than 12 months
Subjects in whom trans-esophageal echocardiography-Doppler assessment is contraindicated or in which mitral regurgitation is not measurable by Transthoracic Echocardiography (TTE)
Subject has a prior history of atrial septal defect (ASD) closure or patient foramen ovale (PFO) closure
Subject has fixed pulmonary artery systolic pressure > 70 mmHG
Subject has known hypersensitivity or contraindication to protocol required procedural or post procedural medication (e.g., anticoagulation therapy) or hypersensitivity to nickel or titanium
Subject has known hypersensitivity to contrast that cannot be adequately premedicated
Female subject who is breast feeding or is pregnant and planning to become pregnant within the study period
Subject is participating in another investigational drug or device study that has not reached its primary endpoint or subject intends to participate in another investigational device clinical trial within 12 months after index procedure
Subject has a history of endocarditis within 6 months of index procedure or evidence of an active systemic infection or sepsis
Subject has oxygen-dependent chronic obstructive pulmonary disease
Subject has documented severe liver disease
Subject has Hgb <8 g/dL, platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <1,000 cells/mm3
Subject has any evidence of intracardiac thrombus